Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECEDENT: Nesiritide vs Dobutamine in Decompensated CHF
NCT00270400Phase 3Completed
- Sponsor
- Scios Inc.
- Start
- Aug 1998
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of nesiritide in heart failure (HF) (3 arms), sponsored by Scios Inc. Primary endpoints: Average heart rate change from baseline at 24 hours, Average hourly premature ventricular beats change from baseline at 24 hours and 1 more. Started Aug 1998; status: completed.
02
Drugs
nesiritide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00270400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270400.